Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice

Journal of Neuroscience

Volumn 18, Issue 6, 1998, Pages 2231-2238

  Koeltzow, Timothy E ^a   Xu, Ming ^b,d   Cooper, Donald C ^a   Hu, Xiu Ti ^a   Tonegawa, Susumu ^b   Wolf, Marina E ^a   White, Francis J ^a,c  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

D3 receptors; Dopamine autoreceptors; Dopamine neurons; Dopamine receptors; Dopamine release; Dopamine synthesis; Mutant mice

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GAMMA BUTYROLACTONE; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; FEEDBACK SYSTEM; MESENCEPHALON; MOUSE; NERVE CELL EXCITABILITY; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0032520839     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.18-06-02231.1998     Document Type: Article

References (64)

1. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949.
2. Aghajanian GK, Bunney BS (1977) Dopamine "autoreceptors": pharmacological characterization by microiontophoretic single unit recording studies. Naunyn Schmiedebergs Arch Pharmacol 297:1-7.
3. 3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 260:177-181.
4. Aretha CW, Sinha A, Galloway MP (1995) Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther 274:609-613.
5. 2 receptor mRNA. Brain Res 564:203-219.
6. 2 receptor antagonist L-741,626. Br J Pharmacol 119:1491-1497.
7. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571.
8. 3 dopamine receptors. Neuropsychopharmacology 12:335-345.
9. Chesselet M-F (1984) Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis. Neuroscience 12:347-375.
10. Chio CL, Lajiness ME, Huff RM (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45:51-60.
11. 2 dopamine receptor classification and its functional implications. Synapse 1:347-388.
12. Cubeddu LX, Huffman IS (1982) Operational characteristics of the inhibitory feedback mechanism for regulation of dopamine release via presynaptic receptors. J Pharmacol Exp Ther 223:497-501.
13. 3 receptor ligand. Eur J Pharmacol 249:R9-R10.
14. Devoto P, Collu M, Muntoni AL, Pistis M, Serra G, Gessa GL, Diana M (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse 20:153-155.
15. 3 receptor in the rat brain. Neuroscience 65:731-745.
16. 3H]dopamine release from rat striatal slices by D-2 dopamine receptors. J Pharmacol Exp Ther 239:442-453.
17. 3H-monoamines from field stimulated rat brain slices. Acta Physiol Scand Suppl 371:35-44.
18. 3 receptor preferring antagonists differentially affect striatal release and metabolism in conscious rats. Eur J Pharmacol 261:327-331.
19. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS (1996) In vivo evidence for preferential role of dopamine D receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261-269.
20. Galloway MP, Wolf ME, Roth RH (1986) Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J Pharmacol Exp Ther 236:689-698.
21. 3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res 681:1-7.
22. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899-913.
23. 3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem 66:2209-2212.
24. 3 receptors. Eur J Pharmacol 272:R1-R3.
25. Healy DJ, Meador-Woodruff JH (1996) Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesoconicolimbic systems. Brain Res 708:38-44.
26. Justice Jr JB (1993) Quantitative microdialysis of neurotransmitters. J Neurosci Methods 48:263-276.
27. Kehr W, Carlsson A, Lindqvist M, Magnusson T, Atack C (1972) Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol 24:744-746.
28. 3 receptor binding affinities. Eur J Pharmacol 277:209-214.
29. Landwehrmeyer B, Mengod G, Palacios JM (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5:145-153.
30. 3 receptor: Chinese hamsters or Chinese whispers. Trends Pharmacol 15:46-47.
31. 3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol 275:R7-R9.
32. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92:1719-1723.
33. 3H]dopamine release from striatal slices. J Neurosci Res 35:192-198.
34. 2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. J Neurosci 10:2587-2600.
35. 2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 86:7625-7628.
36. Meador-Woodruff JH, Damask SP, Watson Jr SJ (1994) Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 91:8297-8301.
37. 3 receptors. Eur J Pharmacol 249:R5-R6.
38. 2 receptor in the rat brain by in situ hybridization histochemistry. Proc Natl Acad Sci USA 86:8560-8564.
39. 2 receptor deficient mice. Neuroscience 79:323-327.
40. Nissbrandt H, Ekman A, Eiksson E, Heilig M (1995) Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. Neuro-Report 6:573-576.
41. O'Hara CM, Uhland-Smith A, O'Malley KL, Todd RD (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther 277:186-192.
42. 3 dopamine receptors. J Neurosci 14:1463-1476.
43. Pugsley TA, Davis M, Akunne HC, Mackenzie RG, Shih YH, Darmma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, Demattos SB, Corbin AE, Glase SA, Wise LD, Dijkstra D, Heffner TG (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-1366.
44. Richtand NM, Kelsoe JR, Segal DS, Kuczenski R (1995) Regional quantification of Dl, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Mol Brain Res 33:97-103.
45. 3 receptor antagonist. (+)-S 14247. Eur J Pharmacol 265:175-177.
46. 3, receptors mediate inhibition of dopamine neuronal activity? Biochem Soc Trans 24.199-201.
47. Sanghera MK, Trulson ME, German DC (1984) Electrophysiological properties of mouse dopamine neurons: in vivo and in vitro studies Neuroscience 12:793-801.
48. Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz J-C, Sokoloff P (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. NeuroReport 6:329-332.
49. Sokoloff P, Schwartz J-C (1995) Novel dopamine receptors half a decade later. Trends Pharmacol 16:270-275.
50. 3) as a target for neuroleptics. Nature 347:146-151.
51. Svensson K, Johansson AM, Magnusson T, Carlsson A (1986) (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 334:234-245.
52. 3 receptors inhibit dopamine release. J Pharmacol Exp Ther 270:475-479.
53. Tecott LH, Brennan TJ, Guh L (1996) Gene targeting approaches to analyze neurotransmitter receptor function. Semin Neurosci 8: 145-152.
54. 3 autoreceptors on nigrostriatal neurons analyzed by antisensc knockdown in vivo. J Neurosci 17:2519-2530.
55. Timmerman W, De Vries JB, Westerink BHC (1990) Effects of D-2 agonists on the release of dopamine: localization of the mechanism of action. Naunyn Schmiedebergs Arch Pharmacol 342:650-654.
56. 4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiol Aging 15:713-719.
57. Walters JR, Roth RH (1976) Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol 296:5-14.
58. Wang RY (1981) Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3:123-140.
59. White FJ, Hu X-T, Zhang X-F, Wolf ME (1995) Repeated administration of cocaine or amphetamine alters neuronal responses to glutamate in the mesoaccumbens dopamine system. J Pharmacol Exp Ther 273:445-454.
60. Wolf ME, Roth RH (1987) Dopamine autoreceptors. In: Dopamine receptors (Creese I, Fraser CM, eds). pp 45-96. New York: Liss.
61. Wolf ME, White FJ, Hu X-T (1994) MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J Neurosci 14:1735-1745.
62. Xu M, Hu X-T, Cooper DC, Moratalla R, Graybiel AM, White FJ, Tonegawa S (1994) Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor deficient mice. Cell 79:945-955.
63. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu X-T, White NM, Graybiel AM, White FJ, Tonegawa S (1997) Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19:838-848.
64. Xue CJ, Ng JP, Li Y, Wolf ME (1996) Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. J Neurochem 67:352-363.